We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (383)
- Scheduling (national classification system) (164)
- Safety monitoring and information (26)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Medicinal cannabis hub (6)
- Clinical trials (5)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
758 result(s) found, displaying 551 to 575
-
Corporate reportsDescribers the interaction, role and responsibilities of the TGA and NATA in relation to the regulation of in-house IVDs
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Corporate reportsNew chemical entities registered in 2017 in Australia.
-
Meeting statementsAdvisory Committee on Medicines
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Corporate reportsAbout compositional guidelines for ingredients permitted for use in listed medicines.
-
Corporate reportsThis guideline is an internationally accepted standard for the designing, conducting, recording and reporting of clinical trials.
-
Scheduling decisions (final)Delegate only final scheduling decisions on NCEs now available
-
Scheduling decisions (interim)Interim decisions to amend, or not amend, the Poisons Standard with respect to substances referred to the March 2018 ACMS/ACCS now available
-
Meeting statementsACM meeting statement, meeting 8, April 2018
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Corporate reportsSubmissions received on the Proposed regulatory changes related to personalised and 3D printed medical devices have been published
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Scheduling submissionsPublic submissions on scheduling matters referred to the ACMS#18, July 2016 (interim decision)
-
Corporate reportsThe TGA has published its Self-Assessment Report for 2016-17
-
-
Scheduling submissionsPublic submissions on matters referred to the July 2017 scheduling meetings, and received during the pre-meeting and interim decision consultation periods, are now available
-
Scheduling submissionsPublic submissions on interim scheduling decisions for substances referred to the November 2017 ACMS/ACCS meetings are now available
-
Scheduling decisions (final)Final decisions for substances referred to the ACMS, ACCS/ACMS, ACCS November 2017 meetings, and delegate only decisions on agricultural and veterinary chemicals and NCEs.
-
Corporate reportsReport detailing prescription medicines registrations for 2017
-
Corporate reportsNew generic medicines and biosimilar medicines registered in 2017
-
Corporate reportsA step-by-step guide for prescription medicines
-
Meeting statementsACM 6 meeting statement has been published